These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 16888216)
1. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216 [TBL] [Abstract][Full Text] [Related]
2. Activity-dependent neuroprotective protein: from gene to drug candidate. Gozes I Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064 [TBL] [Abstract][Full Text] [Related]
3. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Zaltzman R; Alexandrovich A; Trembovler V; Shohami E; Gozes I Peptides; 2005 Aug; 26(8):1520-7. PubMed ID: 16042992 [TBL] [Abstract][Full Text] [Related]
4. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885 [TBL] [Abstract][Full Text] [Related]
5. NAP protects hippocampal neurons against multiple toxins. Zemlyak I; Manley N; Sapolsky R; Gozes I Peptides; 2007 Oct; 28(10):2004-8. PubMed ID: 17869381 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Sokolowska P; Passemard S; Mok A; Schwendimann L; Gozes I; Gressens P Neuroscience; 2011 Jan; 173():156-68. PubMed ID: 21073926 [TBL] [Abstract][Full Text] [Related]
7. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Gozes I; Zaltzman R; Hauser J; Brenneman DE; Shohami E; Hill JM Curr Alzheimer Res; 2005 Apr; 2(2):149-53. PubMed ID: 15974912 [TBL] [Abstract][Full Text] [Related]
8. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Shiryaev N; Pikman R; Giladi E; Gozes I Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979 [TBL] [Abstract][Full Text] [Related]
9. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014 [TBL] [Abstract][Full Text] [Related]
10. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Zemlyak I; Sapolsky R; Gozes I Eur J Pharmacol; 2009 Sep; 618(1-3):9-14. PubMed ID: 19619522 [TBL] [Abstract][Full Text] [Related]
11. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Gozes I Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875 [TBL] [Abstract][Full Text] [Related]
12. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. Beni-Adani L; Gozes I; Cohen Y; Assaf Y; Steingart RA; Brenneman DE; Eizenberg O; Trembolver V; Shohami E J Pharmacol Exp Ther; 2001 Jan; 296(1):57-63. PubMed ID: 11123362 [TBL] [Abstract][Full Text] [Related]
13. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Steingart RA; Gozes I Mol Cell Endocrinol; 2006 Jun; 252(1-2):148-53. PubMed ID: 16704895 [TBL] [Abstract][Full Text] [Related]
15. A novel VIP responsive gene. Activity dependent neuroprotective protein. Gozes I; Zamostiano R; Pinhasov A; Bassan M; Giladi E; Steingart RA; Brenneman DE Ann N Y Acad Sci; 2000; 921():115-8. PubMed ID: 11193814 [TBL] [Abstract][Full Text] [Related]
16. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Vaisburd S; Shemer Z; Yeheskel A; Giladi E; Gozes I Sci Rep; 2015 Nov; 5():16300. PubMed ID: 26553741 [TBL] [Abstract][Full Text] [Related]
17. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241 [TBL] [Abstract][Full Text] [Related]
18. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616 [TBL] [Abstract][Full Text] [Related]
19. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Mandel S; Rechavi G; Gozes I Dev Biol; 2007 Mar; 303(2):814-24. PubMed ID: 17222401 [TBL] [Abstract][Full Text] [Related]
20. Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Braitch M; Kawabe K; Nyirenda M; Gilles LJ; Robins RA; Gran B; Murphy S; Showe L; Constantinescu CS Neuroimmunomodulation; 2010; 17(2):120-5. PubMed ID: 19923857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]